» Articles » PMID: 39251878

Targeting Specific Brain Districts for Advanced Nanotherapies: A Review from the Perspective of Precision Nanomedicine

Abstract

Numerous studies are focused on nanoparticle penetration into the brain functionalizing them with ligands useful to cross the blood-brain barrier. However, cell targeting is also crucial, given that cerebral pathologies frequently affect specific brain cells or areas. Functionalize nanoparticles with the most appropriate targeting elements, tailor their physical parameters, and consider the brain's complex anatomy are essential aspects for precise therapy and diagnosis. In this review, we addressed the state of the art on targeted nanoparticles for drug delivery in diseased brain regions, outlining progress, limitations, and ongoing challenges. We also provide a summary and overview of general design principles that can be applied to nanotherapies, considering the areas and cell types affected by the most common brain disorders. We then emphasize lingering uncertainties that hinder the translational possibilities of nanotherapies for clinical use. Finally, we offer suggestions for continuing preclinical investigations to enhance the overall effectiveness of precision nanomedicine in addressing neurological conditions. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.

Citing Articles

Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies.

Prego-Dominguez J, Laso-Garcia F, Palomar-Alonso N, Perez-Mato M, Lopez-Arias E, Dopico-Lopez A Pharmaceutics. 2025; 17(2).

PMID: 40006575 PMC: 11859612. DOI: 10.3390/pharmaceutics17020208.


New Trends in Brain Shuttle Peptides.

Prades R, Teixido M, Oller-Salvia B Mol Pharm. 2025; 22(3):1100-1109.

PMID: 39899901 PMC: 11881811. DOI: 10.1021/acs.molpharmaceut.4c01327.


Targeting specific brain districts for advanced nanotherapies: A review from the perspective of precision nanomedicine.

Sierri G, Patrucco M, Ferrario D, Renda A, Comi S, Ciprandi M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(5):e1991.

PMID: 39251878 PMC: 11670049. DOI: 10.1002/wnan.1991.

References
1.
Guo Q, Xu S, Yang P, Wang P, Lu S, Sheng D . A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice. J Control Release. 2020; 320:347-362. DOI: 10.1016/j.jconrel.2020.01.039. View

2.
de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

3.
Palomino S, Levine A, Wahl J, Liktor-Busa E, Streicher J, Largent-Milnes T . Inhibition of HSP90 Preserves Blood-Brain Barrier Integrity after Cortical Spreading Depression. Pharmaceutics. 2022; 14(8). PMC: 9416719. DOI: 10.3390/pharmaceutics14081665. View

4.
De Smet L, Ceelen W, Remon J, Vervaet C . Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. ScientificWorldJournal. 2013; 2013:720858. PMC: 3621299. DOI: 10.1155/2013/720858. View

5.
Beghi E . The Epidemiology of Epilepsy. Neuroepidemiology. 2019; 54(2):185-191. DOI: 10.1159/000503831. View